Literature DB >> 22484910

Immunohistochemical analysis of LRIG proteins in meningiomas: correlation between estrogen receptor status and LRIG expression.

Soma Ghasimi1, Hannu Haapasalo, Mine Eray, Katariina Korhonen, Thomas Brännström, Håkan Hedman, Ulrika Andersson.   

Abstract

The leucine-rich repeats and immunoglobulin-like domains (LRIG) protein family is comprised of three integral membrane proteins: LRIG1, LRIG2, and LRIG3. LRIG1 is a negative regulator of growth factor signaling. The expression and subcellular localization of LRIG proteins have prognostic implications in primary brain tumors, such as oligodendrogliomas and astrocytomas. The expression of LRIG proteins has not previously been studied in meningiomas. In this study, the expression of LRIG1, LRIG2, and LRIG3 was analyzed in 409 meningiomas by immunohistochemistry, and potential associations between LRIG protein expression and tumor grade, gender, progesterone receptor status, and estrogen receptor (ER) status were investigated. The LRIG proteins were most often expressed in the cytoplasm, though LRIG1 also showed prominent nuclear expression. Cytoplasmic expression of LRIG1 and LRIG2 correlated with histological subtypes of meningiomas (p = 0.038 and 0.013, respectively). Nuclear and cytoplasmic expression of LRIG1 was correlated with ER status (p = 0.003 and 0.004, respectively), as was cytoplasmic expression of LRIG2 (p = 0.006). This study is the first to examine the expression of LRIG proteins in meningiomas, and it shows a correlation between ER status and the expression of LRIG1 and LRIG2, which suggests a possible role for LRIG proteins in meningioma pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22484910     DOI: 10.1007/s11060-012-0856-x

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  36 in total

1.  Cloning, characterization, and expression of human LIG1.

Authors:  J Nilsson; C Vallbo; D Guo; I Golovleva; B Hallberg; R Henriksson; H Hedman
Journal:  Biochem Biophys Res Commun       Date:  2001-06-29       Impact factor: 3.575

2.  LRIG1 and the liar paradox in prostate cancer: a study of the expression and clinical significance of LRIG1 in prostate cancer.

Authors:  Marcus Thomasson; Baofeng Wang; Peter Hammarsten; Anna Dahlman; Jenny Liao Persson; Andreas Josefsson; Pär Stattin; Torvald Granfors; Lars Egevad; Roger Henriksson; Anders Bergh; Håkan Hedman
Journal:  Int J Cancer       Date:  2011-04-08       Impact factor: 7.396

3.  Paracrine regulation of growth factor signaling by shed leucine-rich repeats and immunoglobulin-like domains 1.

Authors:  Wei Yi; Camilla Holmlund; Jonas Nilsson; Shigeki Inui; Ting Lei; Satoshi Itami; Roger Henriksson; Håkan Hedman
Journal:  Exp Cell Res       Date:  2010-11-16       Impact factor: 3.905

4.  Cytoplasmic LRIG2 expression is associated with poor oligodendroglioma patient survival.

Authors:  Camilla Holmlund; Hannu Haapasalo; Wei Yi; Olayinka Raheem; Thomas Brännström; Helena Bragge; Roger Henriksson; Håkan Hedman
Journal:  Neuropathology       Date:  2009-10-20       Impact factor: 1.906

5.  Perinuclear leucine-rich repeats and immunoglobulin-like domain proteins (LRIG1-3) as prognostic indicators in astrocytic tumors.

Authors:  Dongsheng Guo; Jonas Nilsson; Hannu Haapasalo; Olayinka Raheem; Tommy Bergenheim; Håkan Hedman; Roger Henriksson
Journal:  Acta Neuropathol       Date:  2006-03-11       Impact factor: 17.088

6.  Characterization and tissue-specific expression of human LRIG2.

Authors:  Camilla Holmlund; Jonas Nilsson; Dongsheng Guo; Anna Starefeldt; Irina Golovleva; Roger Henriksson; Håkan Hedman
Journal:  Gene       Date:  2004-05-12       Impact factor: 3.688

7.  Epidermal growth factor receptor family (EGFR, ErbB2-4) in gliomas and meningiomas.

Authors:  Ulrika Andersson; Dongsheng Guo; Beatrice Malmer; A Tommy Bergenheim; Thomas Brännström; Håkan Hedman; Roger Henriksson
Journal:  Acta Neuropathol       Date:  2004-05-18       Impact factor: 17.088

8.  Craniotomy for resection of meningioma in the elderly: a multicentre, prospective analysis from the National Surgical Quality Improvement Program.

Authors:  Chirag G Patil; Anand Veeravagu; Shivanand P Lad; Maxwell Boakye
Journal:  J Neurol Neurosurg Psychiatry       Date:  2009-10-13       Impact factor: 10.154

9.  Familial brain tumours-genetics or environment? A nationwide cohort study of cancer risk in spouses and first-degree relatives of brain tumour patients.

Authors:  Beatrice Malmer; Roger Henriksson; Henrik Grönberg
Journal:  Int J Cancer       Date:  2003-08-20       Impact factor: 7.396

Review 10.  The 2007 WHO classification of tumours of the central nervous system.

Authors:  David N Louis; Hiroko Ohgaki; Otmar D Wiestler; Webster K Cavenee; Peter C Burger; Anne Jouvet; Bernd W Scheithauer; Paul Kleihues
Journal:  Acta Neuropathol       Date:  2007-07-06       Impact factor: 17.088

View more
  8 in total

Review 1.  Genetics of human congenital urinary bladder disease.

Authors:  Adrian S Woolf; Helen M Stuart; William G Newman
Journal:  Pediatr Nephrol       Date:  2013-04-13       Impact factor: 3.714

2.  LRIG2 mutations cause urofacial syndrome.

Authors:  Helen M Stuart; Neil A Roberts; Berk Burgu; Sarah B Daly; Jill E Urquhart; Sanjeev Bhaskar; Jonathan E Dickerson; Murat Mermerkaya; Mesrur Selcuk Silay; Malcolm A Lewis; M Beatriz Orive Olondriz; Blanca Gener; Christian Beetz; Rita E Varga; Omer Gülpınar; Evren Süer; Tarkan Soygür; Zeynep B Ozçakar; Fatoş Yalçınkaya; Aslı Kavaz; Burcu Bulum; Adnan Gücük; Wyatt W Yue; Firat Erdogan; Andrew Berry; Neil A Hanley; Edward A McKenzie; Emma N Hilton; Adrian S Woolf; William G Newman
Journal:  Am J Hum Genet       Date:  2013-01-11       Impact factor: 11.025

Review 3.  LRIG1, a regulator of stem cell quiescence and a pleiotropic feedback tumor suppressor.

Authors:  Yibing Ji; Rahul Kumar; Abhiram Gokhale; Hseu-Ping Chao; Kiera Rycaj; Xin Chen; Qiuhui Li; Dean G Tang
Journal:  Semin Cancer Biol       Date:  2021-01-18       Impact factor: 17.012

Review 4.  LRIG and cancer prognosis.

Authors:  David Lindquist; Samuel Kvarnbrink; Roger Henriksson; Håkan Hedman
Journal:  Acta Oncol       Date:  2014-09-02       Impact factor: 4.089

5.  Decreased LRIG1 in fulvestrant-treated luminal breast cancer cells permits ErbB3 upregulation and increased growth.

Authors:  M M Morrison; M M Williams; D B Vaught; D Hicks; J Lim; C McKernan; L Aurisicchio; G Ciliberto; C Simion; C Sweeney; R S Cook
Journal:  Oncogene       Date:  2015-07-06       Impact factor: 9.867

Review 6.  LRIG1 is a triple threat: ERBB negative regulator, intestinal stem cell marker and tumour suppressor.

Authors:  Y Wang; E J Poulin; R J Coffey
Journal:  Br J Cancer       Date:  2013-04-04       Impact factor: 7.640

7.  LRIG2 expression and prognosis in non-small cell lung cancer.

Authors:  Guangchuan Wang; Jie Wu; Huijuan Song
Journal:  Oncol Lett       Date:  2014-05-19       Impact factor: 2.967

8.  Expression of LRIG1 is Associated With Good Prognosis for Human Non-small Cell Lung Cancer.

Authors:  Yuzhi An; Zibo Zhao; Pengju Ou; Guangchuan Wang
Journal:  Medicine (Baltimore)       Date:  2015-11       Impact factor: 1.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.